Images List Premium Download Classic

Leukemia

Leukemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
Oncoethix Gmbh
April 12, 2018 - N°20180098997

The invention is a method for treating patients with cancer comprising administering to the patient a safe and effective dose of (s)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(4-hydroxyphenyl)acetamideor a pharmaceutically acceptable salt or hydrate thereof, wherein the dose is between about 40 mg once per per day and about 120 mg once per ...
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4...
Sunesis Pharmaceuticals, Inc.
April 12, 2018 - N°20180098975

Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions ...
Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment ...
Flavocure Biotech Llc
April 12, 2018 - N°20180098961

An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of apigenin, cannflavin. A. Cannflavin b, cannflavin c, chrysoeriol, cosmosiin, flavocannabiside, kaempferol, luteolin, myricetin, orientin, isoorientin (homoorientin), quercetin (+)-taxifolin, vitexin, and isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antibodies to il-6 and use thereof
Alderbio Holdings Llc
April 05, 2018 - N°20180092999

The present invention is directed to therapeutic methods using il-6 antagonists such as an ab1 antibody or antibody fragment having binding specificity for il-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum ...
Ldl quantitation and methods of use
April 05, 2018 - N°20180092964

The present invention features, in certain aspects, methods of promoting endocytosis of ldl with α1pi or peptides derived from α1pi. The present invention also provides methods for decreasing ldl levels in response to α1pi augmentation therapy. In preferred embodiments, the methods are suitable for a subject who is suffering from a disease or disorder ...
Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
Rasna Research Inc.
April 05, 2018 - N°20180092857

The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (mds) or cancer, for example, npm1-mutated acute myeloid leukemia (aml), by administration of the compositions of the disclosure.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pyrazolone compounds and uses thereof
Tempest Therapeutics, Inc.
March 22, 2018 - N°20180079745

The invention disclosed herein is directed to compounds of formula i [formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of formula ...
Compositions and methods of treating acute myeloid leukemia
Beth Israel Deaconess Medical Center
March 22, 2018 - N°20180078650

The present invention provides compositions and methods for treating acute myeloid leukemia.
Method for treating infectious diseases using emissive energy
Marv Enterprises, Llc
March 22, 2018 - N°20180078641

The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser ...
Micronutrient formulations for environmental exposure applications
March 22, 2018 - N°20180078579

A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin c, vitamin e, n-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin a (palmitate), vitamin d-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, d-biotin, selenium (1...
Therapeutic agent for intractable leukemia
March 22, 2018 - N°20180078567

The drug (b) is a steroidal anti-inflammatory drug; and relates to a therapy for intractable leukemia.
Method for predicting prognostic results of diseases
National Taiwan University
March 15, 2018 - N°20180073081

The invention is directed to a method to predict prognostic results for diseases including acute myeloid leukemia (aml) by analyzing novel markers which comprises microrna/mrna (mirna/mrna) pairings. In particular, the mirna/mrna pairings are a kind of npm1 mutation-modulated mirna/mrna regulation pairs.
5-substituted 7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo4,3-d]pyrimidine derivatives, use thereof as medicaments, and ...
Ustav Experimentalni Botaniky Av Cr, V.v.i.
March 15, 2018 - N°20180072736

5-substituted-7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidines are potent inhibitors of protein kinases, especially cyclin-dependent kinases such as cdk2 and cdk5, and display antileukemic, pro-apoptotic, antiangiogenic and anticancer activities. The invention also relates to processes for their preparation, to pharmaceutical compositions and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation, apoptosis, angiogenesis ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination therapy comprising an inhibitor of jak, cdk, and pim
Novartis Ag
March 15, 2018 - N°20180071296

The present invention relates to a pharmaceutical combination which comprises (a) a jak inhibitor compound, (b) a cdk inhibitor, and (c) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use ...
Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1h)-one derivatives
Korea Institute Of Science And Technology
March 08, 2018 - N°20180065969

The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1h)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line oci-aml3 having a nras mutant gene while having low inhibitory activity for wild type nras and has activity of inhibiting gck and ack1 ...
Method of treating leukemia based on gene expression of clock genes
King Abdullah International Medical Research Center
March 01, 2018 - N°20180057886

A method of treating leukemia in a patient, the method including obtaining a plasma sample from a patient at a first time point and at a second time point, measuring a gene expression level of a set of core clock genes, and at least one of a first set of peripheral clock genes and a second set of peripheral clock ...
Inhibitors of bcr-abl mutants and use thereof
The Regents Of The University Of Michigan
March 01, 2018 - N°20180057479

Inhibitor compounds of bcr-abl and bcr-abl mutants including bcr-abl t315i mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.
Anti-cd89 cytotoxic complex
Friedrich-alexander-universitÄt Erlangen- NÜrnberg
February 22, 2018 - N°20180050102

Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor cd89 (e. G. With an anti cd89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably pseudomonas exotoxin a); to nucleic ...
Cml therapeutic agents with reduced drug-resistance and side-effect comprising 1,6-disubstituted indole compounds
Korea Institute Of Science And Technology
February 22, 2018 - N°20180050036

The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.
Novel antibodies and uses thereof
Cantargia Ab
February 15, 2018 - N°20180044425

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (il1rap) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human il1rap. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such ...
Combination treatment protocol
Bionomics Limited
February 15, 2018 - N°20180042887

The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (cll).
Loading